Molecular biology has entered a period where several core technologies are advancing simultaneously, reshaping what researchers can measure, edit, and build. Long-read sequencing now reaches previously unreadable stretches of the genome, single-cell methods capture gene activity and chromatin state together, spatial techniques map molecules within intact tissues, and genome editors have grown far more precise than the original cut-and-paste approach of CRISPR. These developments are not isolated curiosities; they feed into one another, and understanding where each stands helps make sense of where research and medicine are headed.
Long-Read Sequencing and the First Complete Human Genome
For years, the standard way to read DNA involved chopping it into short fragments and reassembling the puzzle computationally. That worked well for most of the genome, but it left roughly eight percent unfinished because short reads simply could not span the highly repetitive stretches found in centromeres, segmental duplications, and the short arms of certain chromosomes. Long-read sequencing changed the equation. Platforms from Oxford Nanopore Technologies and Pacific Biosciences now routinely read DNA fragments tens to hundreds of thousands of bases long, which is enough to bridge those repetitive regions and reveal large structural rearrangements that short reads miss entirely.1PubMed. Long-Read DNA Sequencing: Recent Advances and Remaining Challenges
The payoff arrived in 2022 when the Telomere-to-Telomere Consortium published the first truly gapless human genome sequence. That assembly, called T2T-CHM13, spans about 3.055 billion base pairs and adds roughly 200 million base pairs of sequence that previous reference genomes had left out, including nearly 2,000 predicted genes.2PubMed Central. The complete sequence of a human genome Having a complete reference matters beyond pure curiosity. Clinical geneticists searching for disease-causing structural variants now have a map that includes the regions where many of those variants hide. Long-read platforms can accurately find structural variants throughout the genome, including in the repetitive sequences and segmental duplications that were previously unreachable.3PubMed Central. Long-Read Sequencing and Structural Variant Detection: Unlocking the Hidden Genome in Rare Genetic Disorders
Reading RNA Without Rewriting It
Most sequencing workflows require converting RNA into DNA before reading it, a step that strips away chemical modifications on the original RNA molecule. Those modifications matter because they influence how RNA is processed, translated, and degraded. Nanopore direct RNA sequencing sidesteps the conversion step entirely, threading native RNA strands through a protein pore and reading the electrical signal changes caused by each passing nucleotide, modifications included.4PubMed Central. Advances in Detecting RNA Modifications Using Direct RNA Nanopore Sequencing The approach is still noisier than DNA sequencing, and throughput lags behind, but it opens a window into the “epitranscriptome,” the layer of chemical marks on RNA that was essentially invisible to earlier methods. As computational tools for interpreting those noisy signals improve, direct RNA sequencing is poised to become a routine way to study how cells fine-tune gene expression beyond what the DNA sequence alone dictates.
Single-Cell and Multi-Omics Profiling
A tissue biopsy contains millions of cells, and averaging their gene activity together can mask the cell types and states that drive disease. Single-cell RNA sequencing has addressed this by reading transcripts from individual cells, uncovering remarkable heterogeneity in tumors and healthy tissues alike.5PubMed Central. XYZeq: Spatially resolved single-cell RNA sequencing reveals expression heterogeneity in the tumor microenvironment In pancreatic cancer, for instance, single-cell transcriptomics has revealed heterogeneous changes within both the tumor cells and the surrounding microenvironment during the shift from early, noninvasive stages to fully invasive disease.6PubMed. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma
The field’s current frontier is measuring more than one molecular layer from the same cell. Gene expression tells you what a cell is doing right now, but chromatin accessibility tells you what it could do and what regulatory switches are open or closed. Methods like ISSAAC-seq demonstrated that joint profiling of chromatin accessibility and gene expression from the same nucleus could reveal cell-type-specific regulatory elements and even uncover chromatin-level heterogeneity within cell types that look identical by gene expression alone.7PubMed Central. ISSAAC-seq enables sensitive and flexible multimodal profiling of chromatin accessibility and gene expression in single cells
More recently, a method called Parallel-seq pushed this approach to a much larger scale and lower cost. Applied to lung tumor samples, it generated over 200,000 joint chromatin-and-RNA profiles, enabling researchers to characterize copy-number variations, extrachromosomal DNA, and hundreds of thousands of cell-type-specific regulatory events. The developers reported a cost roughly two orders of magnitude lower than existing alternatives.8Cell Systems. A method for joint analysis of chromatin accessibility and gene expression in the same single cells reveals cancer-specific regulatory programs When the cost of a technique drops that dramatically, it stops being a boutique experiment and starts becoming a standard part of the toolkit.
Spatial Transcriptomics and Mapping Molecules in Place
Single-cell methods tell you what each cell is expressing, but they typically require dissociating tissue into a suspension, which destroys the physical context. Spatial transcriptomics fills that gap by measuring gene expression while preserving the architecture of the tissue. The technology has been adopted across neuroscience, developmental biology, plant biology, and oncology.9PubMed Central. Exploring tissue architecture using spatial transcriptomics
Two broad families of spatial methods exist. Sequencing-based approaches capture transcripts at defined spots on a tissue section. One early demonstration combined microarray-based spatial transcriptomics with single-cell RNA sequencing from the same pancreatic tumor sample, producing a layered view that tied cell identities to their physical locations.10Nature Biotechnology. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas Imaging-based approaches take a different route. MERFISH (multiplexed error-robust fluorescence in situ hybridization) uses sequential rounds of fluorescent labeling and error-correcting codes to count individual RNA molecules in place, achieving quantification of hundreds to thousands of RNA species in single cells.11PubMed Central. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells The method has been paired with cellular-structure imaging to determine where within a cell specific transcripts are compartmentalized, adding a subcellular dimension to spatial mapping.12PubMed Central. Spatial transcriptome profiling by MERFISH reveals subcellular RNA compartmentalization and cell cycle-dependent gene expression
A recent extension called weMERFISH scaled this imaging approach to entire zebrafish embryos. Researchers quantified the expression of 495 genes at subcellular resolution and generated an online atlas covering over 25,000 genes and nearly 295,000 chromatin regions during embryonic development.13PubMed. Whole-embryo spatial transcriptomics at subcellular resolution from gastrulation to organogenesis That kind of whole-organism atlas at subcellular resolution would have been science fiction a decade ago.
Precision Genome Editing and In Vivo Delivery
The original CRISPR-Cas9 approach works by cutting both strands of DNA at a target site, then relying on the cell’s own repair machinery to introduce a desired change. The problem is that double-strand breaks often get repaired imprecisely, introducing unwanted insertions or deletions. Newer tools called base editors and prime editors sidestep this by chemically converting one DNA letter into another or writing in short new sequences without intentionally breaking both strands.14PubMed Central. CRISPR/Cas9-Based Engineering of the Epigenome The reduced reliance on double-strand breaks lowers the risk of messy repair outcomes, making these editors more predictable for therapeutic applications.
Editing tools are only useful if you can get them into the right cells. Lipid nanoparticles have emerged as the leading delivery vehicle for nucleic acids in vivo, largely because they protect their cargo in the bloodstream and can be engineered to target specific cell types.15PubMed. The future of genetic medicines delivered via targeted lipid nanoparticles to leukocytes One striking proof of concept involved targeting the CD45 receptor on blood-forming stem cells. Researchers developed ionizable lipid nanoparticles that, after a single intravenous injection into a fetus in a mouse model, achieved long-term gene modulation of those stem cells. The same platform was then optimized to deliver CRISPR-based cargo and demonstrated gene editing at a target site in fetal blood stem cells.16PubMed Central. In utero delivery of targeted ionizable lipid nanoparticles facilitates in vivo gene editing of hematopoietic stem cells Correcting a genetic disease before birth, by injecting nanoparticles rather than transplanting cells, remains far from the clinic, but the mouse data showed that the concept is technically feasible.
Functional Genomic Screens Using CRISPR Libraries
Beyond editing individual genes, CRISPR has become a powerful screening tool. By creating libraries of guide RNAs that target every gene in the genome, researchers can systematically knock out, silence, or activate genes across an entire cell population and see which changes affect a trait of interest. Combining all three approaches in a single experiment can reveal complex gene networks that no single screen would catch. One group applied knockout, inhibition, and activation screens together to identify the network of genes driving resistance to a cancer drug, illustrating how pairing loss-of-function and gain-of-function data adds confidence to target identification.17Scientific Reports. Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance
Pooled CRISPR screens in pancreatic cancer cells have similarly uncovered that activation of certain drug-efflux pumps and transcriptional co-repressor complexes can confer resistance to multiple drugs at once, pointing toward mechanisms of multi-drug resistance that would be difficult to find without a genome-wide approach.18PubMed Central. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition These screens are becoming a standard early step in drug-target discovery, replacing years of candidate-by-candidate experiments with a single, comprehensive assay.
AI-Powered Structure Prediction and Cryo-EM at Small Scales
Knowing the three-dimensional shape of a protein is essential for understanding how it works and for designing drugs that fit into its binding pockets. Experimental methods like X-ray crystallography and cryo-electron microscopy provide gold-standard structures, but they are slow and often fail for proteins that resist crystallization. AlphaFold2 changed the landscape by using machine learning to predict protein structures with high accuracy, and the team applied it at a scale covering about 98.5 percent of human proteins.19Nature. Highly accurate protein structure prediction for the human proteome AlphaFold 3 extended this capability further, predicting the joint structure of complexes that include proteins, nucleic acids, small molecules, ions, and modified residues within a single framework.20Nature. Accurate structure prediction of biomolecular interactions with AlphaFold 3
Meanwhile, cryo-electron microscopy itself has been pushing into new territory. The technique has traditionally worked best on large molecular complexes because smaller proteins generate weaker signals and are harder to align computationally. A recent study reported cryo-EM structures of two protein-ligand complexes near the lower size limit: one with a structurally ordered mass of about 41 kilodaltons resolved at 2.4 angstroms, and another at about 32 kilodaltons, which falls below the theoretical 38 kilodalton threshold, resolved at 3.4 angstroms. Both maps clearly showed the bound drug molecules.21Nature Communications. High-resolution cryo-EM structures of small protein–ligand complexes near the theoretical size limit This matters for drug discovery because many pharmacologically interesting protein domains are small. Being able to visualize a drug bound to a small kinase domain, rather than needing to crystallize it or fuse it to a larger scaffold, removes a bottleneck that has slowed structure-based drug design for years.
Molecular Diagnostics From Blood Draws and Paper Strips
Two threads in molecular diagnostics are converging to move more of the testing process out of centralized labs. The first is liquid biopsy. Tumors shed fragments of DNA into the bloodstream, and analyzing the methylation patterns on that cell-free DNA can reveal information about cancer at very early stages. DNA methylation changes are one of the hallmarks of many cancers and tend to appear early during the disease’s development, making them attractive biomarkers. Researchers are developing systemic analysis of these methylation profiles for early cancer detection, monitoring for residual disease after treatment, predicting how a patient will respond to therapy, and even tracing the tissue of origin of a tumor.22PubMed. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA
The second thread involves adapting CRISPR for diagnostics rather than editing. Certain CRISPR enzymes, including Cas13a, exhibit a “collateral effect”: once they recognize and bind their target RNA or DNA sequence, they begin indiscriminately chopping nearby nucleic acids. By coupling this collateral activity with a labeled reporter molecule, researchers built CRISPR-based diagnostics that detect specific DNA or RNA sequences with sensitivity down to the attomolar range and single-base-mismatch specificity.23PubMed Central. Nucleic acid detection with CRISPR-Cas13a/C2c2 Several CRISPR family members, including Cas13, Cas12a, and Cas14, share this collateral-cleavage behavior and have been adapted for pathogen detection. When these systems are paired with lateral-flow strips, the format resembles a home pregnancy test but detects viral or bacterial nucleic acids.24PubMed. Nucleic Acid Detection Using CRISPR/Cas Biosensing Technologies Ongoing work is integrating CRISPR-based detection into smart devices for true point-of-care deployment.25PubMed Central. Towards Point of Care CRISPR-Based Diagnostics: From Method to Device
Proteomics at the Single-Molecule and Spatial Level
Genomics and transcriptomics have raced ahead partly because nucleic acids can be amplified, making even trace amounts detectable. Proteins cannot be amplified, which makes proteomic analysis inherently harder at low-input levels. New single-molecule protein sequencing and identification technologies aim to close that gap, working alongside innovations in mass spectrometry toward the goal of broad sequence coverage from single-cell amounts of material.26PubMed Central. The emerging landscape of single-molecule protein sequencing technologies If these methods mature, they will enable direct measurement of proteins at sensitivity levels that match what transcriptomics already offers for RNA.
Spatial proteomics brings a complementary angle. Rather than grinding up tissue and measuring bulk protein content, these methods detect and quantify proteins within intact tissue sections at subcellular resolution. In melanoma, spatial proteomics has been used to map the tumor microenvironment, revealing cellular interactions, signaling states, and potential therapeutic targets tied to specific tissue regions.27PubMed Central. Spatial proteomics of the tumor microenvironment in melanoma: current insights and future directions A separate approach called activity-based protein profiling uses small chemical probes to measure what proteins are actually doing inside a cell, rather than just whether they are present. This chemoproteomic strategy interrogates protein function directly within complex mixtures, which is useful for drug discovery because a protein’s activity state often matters more than its abundance.28PubMed Central. Activity-based protein profiling: A graphical review
Cell-Free Systems and Droplet Microfluidics
Not every experiment needs a living cell. Cell-free transcription-translation systems extract the molecular machinery from cells and run it in a test tube, allowing researchers to prototype genetic circuits and metabolic pathways without the complications of cell growth, division, or unwanted metabolic interference. The approach dramatically shortens design-build-test cycles.29PubMed. Cell-free systems: A synthetic biology tool for rapid prototyping in metabolic engineering Early wins include translating prototype designs into medical test kits for on-site identification of viruses like Zika and Ebola, and enabling rapid debugging and redesign of gene circuit cascades.30PubMed Central. Cell-free synthetic biology for in vitro prototype engineering
Droplet microfluidics adds a physical infrastructure to single-cell and cell-free work. By encapsulating individual cells or reactions inside tiny droplets, each one acting as an independent reaction vessel, microfluidic devices enable high-throughput screening at scales that would be impractical with traditional well plates. Droplets range from nanoliters to picoliters, and researchers have used them for single-cell phenotypic screening, studies of cell-to-cell and cell-to-microbe interactions, and genomic analysis.31PubMed Central. Droplet Microfluidics for Advanced Single-Cell Analysis The combination of droplet microfluidics with single-cell sequencing is, in practice, what makes many of the single-cell experiments described earlier economically feasible. Without the ability to partition thousands of cells into individual droplets cheaply, the per-cell cost of sequencing would remain prohibitive for large-scale studies. The hardware and the biology are evolving together, and the techniques covered here increasingly depend on one another rather than operating in isolation.